Venus Remedies Ltd

Venus Remedies will hold a meeting of the Board of Directors of the Company on 8 July 2025.Powered by Capital Market - Live

However, revenue from operations decreased marginally to Rs 194.97 crore in Q4 FY25, as against Rs 195.16 crore posted in the corresponding quarter of the previous year. Profit before tax surged 77.57% to Rs 31.04 crore in Q4 FY25, compared to Rs 17.48 crore in Q4 FY24. Total expenses slipped 6.01% YoY to Rs 170.69 crore in Q4 FY25. The cost of materials consumed was Rs 104.21 crore (up 23.80% YoY), while employee benefits expenses stood at Rs 21.16 crore (up 7.35% YoY) during the March 2025 quarter. During Q4 FY25, EBITDA stood at Rs 35.77 crore, up 52.92% from Rs 23.39 crore posted in the corresponding quarter last year. On a full-year basis, the company's consolidated net profit surged 59.07% to Rs 45.32 crore on a 7.72% jump in revenue from operations to Rs 647.89 crore in FY25 over FY24. Venus Remedies is an Indian research-driven pharmaceutical company dedicated to developing innovative solutions to improve patient outcomes. Powered by Capital Market - Live

Net profit of Venus Remedies rose 99.81% to Rs 21.00 crore in the quarter ended March 2025 as against Rs 10.51 crore during the previous quarter ended March 2024. Sales declined 0.10% to Rs 194.97 crore in the quarter ended March 2025 as against Rs 195.16 crore during the previous quarter ended March 2024. For the full year,net profit rose 59.13% to Rs 45.32 crore in the year ended March 2025 as against Rs 28.48 crore during the previous year ended March 2024. Sales rose 7.72% to Rs 647.89 crore in the year ended March 2025 as against Rs 601.45 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales194.97195.16 0 647.89601.45 8 OPM %14.879.98 -9.819.91 - PBDT35.7523.37 53 84.4371.09 19 PBT31.0417.46 78 61.9244.64 39 NP21.0010.51 100 45.3228.48 59 Powered by Capital Market - Live

Venus Remedies will hold a meeting of the Board of Directors of the Company on 26 May 2025.Powered by Capital Market - Live

The drug is intended for the treatment of bloodstream infections caused by polymyxin B (PMB)-susceptible strains in adults. Developed by the Venus Medicine Research Centre (VMRC)'the R&D arm of Venus Remedies'VRP-034 is a novel supramolecular cationic (SMC) formulation of polymyxin B sulphate. It has been designed specifically to mitigate the nephrotoxic effects often associated with conventional polymyxin B therapy, a critical concern in treating drug-resistant infections. The QIDP status has been granted under the Generating Antibiotic Incentives Now (GAIN) Act, a U.S. initiative aimed at encouraging the development of new antibiotics to combat serious or life-threatening infections. With this designation, VRP-034 now qualifies for several key regulatory benefits, including priority review, eligibility for fast track designation, and an additional five years of market exclusivity upon receiving FDA approval. Polymyxins like PMB and colistin are critical last-resort antibiotics for treating multidrug-resistant (MDR) infections but are often limited by high rates of nephrotoxicity, affecting up to 60% of patients. Venus Remedies' investigational product, VRP-034, aims to overcome this limitation by maintaining the therapeutic profile of PMB while significantly reducing kidney toxicity'by up to 70%'as shown in preclinical studies. It has demonstrated strong efficacy against resistant pathogens and a favorable safety profile using advanced testing models. The recent QIDP designation by the US FDA highlights the drug's potential and reinforces the company's focus on tackling antimicrobial resistance. Venus Remedies is a pharmaceutical company specializing in critical care injectables. It reported a consolidated net profit surged 186.13% to Rs 19.60 crore on a 23.31% increase in revenue from operations to Rs 176.85 crore in Q3 FY25 over Q3 FY24. Powered by Capital Market - Live

MET-X, a metallo-beta-lactamase (MBL) inhibitor, targets drug-resistant Gram-negative bacteria, a significant concern in India due to high meropenem resistance. Venus Remedies will initiate Phase I trials in India, testing MET-X with meropenem, progressing to Phase II/III trials for drug-resistant complicated urinary tract infections (cUTIs). The company's established expertise in meropenem marketing and manufacturing is crucial for this development. MET-X's broad-spectrum action combats Gram-negative bacteria that resist beta-lactam antibiotics, offering a solution to antibiotic resistance. Clinical trials in India will adhere to international standards (FDA, EMA, MHRA), facilitating global commercialization. The agreement also allows for potential expansion to other MET-X combinations. Venus Remedies is an Indian research-driven pharmaceutical company dedicated to developing innovative solutions to improve patient outcomes. Venus Remedies reported a consolidated net profit surged 186.13% to Rs 19.60 crore on a 23.31% increase in revenue from operations to Rs 176.85 crore in Q3 FY25 over Q3 FY24. Powered by Capital Market - Live

Stallion India Fluorochemicals Ltd, Bliss GVS Pharma Ltd, BEML Land Assets Ltd and Repro India Ltd are among the other gainers in the BSE's 'B' group today, 05 February 2025.Venus Remedies Ltd surged 20.00% to Rs 348.6 at 12:03 IST. The stock was the biggest gainer in the BSE's 'B' group. On the BSE, 7966 shares were traded on the counter so far as against the average daily volumes of 2333 shares in the past one month. Stallion India Fluorochemicals Ltd spiked 14.14% to Rs 107.78. The stock was the second biggest gainer in 'B' group. On the BSE, 5.49 lakh shares were traded on the counter so far as against the average daily volumes of 2.75 lakh shares in the past one month. Bliss GVS Pharma Ltd soared 13.65% to Rs 159. The stock was the third biggest gainer in 'B' group. On the BSE, 1.47 lakh shares were traded on the counter so far as against the average daily volumes of 67230 shares in the past one month. BEML Land Assets Ltd exploded 13.45% to Rs 236.15. The stock was the fourth biggest gainer in 'B' group. On the BSE, 50714 shares were traded on the counter so far as against the average daily volumes of 4522 shares in the past one month. Repro India Ltd advanced 11.58% to Rs 560. The stock was the fifth biggest gainer in 'B' group. On the BSE, 4269 shares were traded on the counter so far as against the average daily volumes of 3197 shares in the past one month. Powered by Capital Market - Live

Profit before exceptional items and tax in Q3 FY25 was at Rs 14.97 crore, up 92.42% from Rs 7.78 crore recorded in Q3 FY24. Exceptional profit stood at Rs 9.91 crore in Q3 FY25. Total expenses advanced 18.79% YoY to Rs 163.92 crore in Q3 FY23. The cost of materials consumed was at Rs 97.52 crore (up 11.69% YoY), while employee benefits expenses stood at Rs 19.55 crore (up 12.68% YoY) during the December 2024 quarter. During Q3 FY25, EBIDTA stood at Rs 20.39 crore, up 41.7% from Rs 14.39 crore posted in corresponding quarter last year. On a nine-month basis, the company's net profit jumped 35.45% to Rs 24.34 crore on 11.48% rise in revenue from operations to Rs 452.92 crore in 9M FY24 over 9M FY23. Venus Remedies is among the 10 leading fixed-dose injectable manufacturers in the world. Powered by Capital Market - Live

Net profit of Venus Remedies rose 186.13% to Rs 19.60 crore in the quarter ended December 2024 as against Rs 6.85 crore during the previous quarter ended December 2023. Sales rose 23.32% to Rs 176.86 crore in the quarter ended December 2024 as against Rs 143.42 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales176.86143.42 23 OPM %10.388.39 - PBDT20.3814.32 42 PBT14.977.78 92 NP19.606.85 186 Powered by Capital Market - Live

Venus Remedies will hold a meeting of the Board of Directors of the Company on 4 February 2025.Powered by Capital Market - Live